About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological diseases. Catalyst is currently developing amifampridine phosphate (with the proposed tradename of Firdapse) for the treatment of Lambert - Eaton Myasthenic Syndrome (LEMS). LEMS is a rare, autoimmune, neuromuscular disorder in which the body attacks and interferes with the communication between nerve and muscle cells primarily causing progressively severe muscle weakness and fatigue. Catalyst has completed a pivotal phase III, multi-centered clinical trial that showed amifampridine phosphate to be safe and effective in the treatment of patients with LEMS and is currently conducting a second, similar trial. Additionally, Catalyst is currently conducting a separate clinical trial of amifampridine phosphate in patients with Congenital Myasthenic Syndromes (CMS). Catalyst is also preparing to launch an additional clinical trial amifampridine phosphate in patients with MuSK Positive Myasthenia Gravis (MuSK-MG).